Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.68 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21121062 | 1.00 | FFAR1 (0.68) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL22800018 | 1.00 | FFAR1 (0.68) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL21121217 | 1.00 | FFAR1 (0.68) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL21121216 | 1.00 | FFAR1 (0.68) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL21121064 | 1.00 | FFAR1 (0.68) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL21121428 | 0.99 | FFAR1 (0.70) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL21121431 | 0.99 | FFAR1 (0.70) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL22799988 | 0.99 | FFAR1 (0.70) | FFAR1MMP9MMP8MMP13 | |
| SCHEMBL21121141 | 0.96 | FFAR1 (0.73) | FFAR1 | |
| SCHEMBL21121140 | 0.96 | FFAR1 (0.73) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| CN-111757770-B | 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3737470-B1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2022-12-14 | — | — | EP | disclosed |
| US-20200399198-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2020-12-24 | — | — | US | disclosed |
| CN-111757770-A | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2020-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399198-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | GPR119, FFAR1, GPR65 | FFAR1 2/4885MMP9 4821/4885MMP8 4861/4885 |
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | GPR119, FFAR1, GPR65 | FFAR1 2/4885MMP9 4821/4885MMP8 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.